Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Teleflex (TFX)

Teleflex adds $200 million to delayed draw term loan tied to Vascular Intervention deal

Neutral Impact 3 of 5 financing Written later

On June 24, 2025, Teleflex and certain subsidiaries amended their Third Amended and Restated Credit Agreement to add $200 million of delayed draw term loan commitments, bringing the total to $700 million. The funds become available to draw on the date Teleflex completes its acquisition of the Vascular Intervention business segment of MS Holding II SE, subject to customary conditions. Other terms of the facility were described as substantially unchanged.

Key points

  • Amendment No. 2 dated June 24, 2025, with JPMorgan Chase Bank, N.A. as administrative agent
  • Additional delayed draw term loan commitments of $200 million, for a total of $700 million
  • Commitments are available to draw only on the closing date of the pending acquisition of the Vascular Intervention business segment of MS Holding II SE

The filing

CompanyTeleflex (TFX)
Form8-K, current report
Filed with the SECJun 27, 2025, 5:43 PM ET
Accession number0000096943-25-000107

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.